Pharmacological coronary spasm provocative testing in clinical practice: A French Coronary Atheroma and Interventional Cardiology Group (GACI) position paper

Fabien Picard (1, 2) , Julien Adjedj (3) , Jean-Philippe Collet (4, 5, 6, 7) , Eric van Belle (8) , Jacques Monsegu (9) , Bernard Karsenty , Patrick Dupouy , Marine Quillot , Guillaume Bonnet (1) , Alexandre Gautier (10) , Guillaume Cayla (11) , Hakim Benamer (12)

1 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
2 Hôpital Cochin [AP-HP]
3 Institut Arnault Tzanck
4 CHU Pitié-Salpêtrière [AP-HP]
5 Groupe Action
6 Institut de cardiologie [CHU Pitié-Salpêtrière]
7 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
8 RNMCD - Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011
9 GHM - Groupe Hospitalier Mutualiste [Grenoble]
10 ICPS - Institut Cardiovasculaire Paris Sud
11 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
12 Hôpital Privé Jacques Cartier [Massy]

Highlights  •VSA is common and is involved in many clinical scenarios.  •These include chronic and acute coronary syndromes, SCD, arrhythmia and syncope.  •VSA is underdiagnosed and provocative tests are rarely performed.  •A lack of uniform protocol decreases the use and performance of provocative tests.  •This accounts for VSA underestimation.  •This GACI position paper gives clear indications for provocative tests.  •The paper also addresses testing conditions, drug protocols and positivity criteria.

Domaines: Sciences du Vivant [q-bio]

Fabien Picard, Julien Adjedj, Jean-Philippe Collet, Eric van Belle, Jacques Monsegu, et al.. Pharmacological coronary spasm provocative testing in clinical practice: A French Coronary Atheroma and Interventional Cardiology Group (GACI) position paper. Archives of cardiovascular diseases, 2023, 116 (12), pp.590-596. ⟨10.1016/j.acvd.2023.10.002⟩. ⟨hal-04380263⟩